The HER2 −ve phenotype is a reliable prognostic biomarker for breast cancer receptor characteristics.11-14 addition, the HER2 −ve marker, regardless of estrogen (ER) or progesterone (PR) status, has been reported as a marker for aggressive breast cancer phenotypes.15-16 Based on the imaging criteria, staging was also dichotomized into low stage (stage I/II) and high stage (stage III/IV). Here, ERBB2 is linked to breast carcinoma.